Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

Rhea-AI Summary

Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company, announced that CEO Pete Salzmann, M.D., will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day on November 14, 2022, at 3:55 pm Eastern Time. The webcast will be accessible through the company's Investor Relations section. Immunovant focuses on developing therapies for autoimmune diseases, particularly with FcRn inhibitor technology, addressing significant patient needs.

News Market Reaction – IMVT

+5.15%

+5.15% Session move

In the trading session that priced this news, IMVT gained 5.15%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day, taking place November 14^th-15^th, 2022.

Guggenheim 4th Annual Immunology and Neurology Day fireside chat details:
Date:	Monday, November 14th, 2022
Time:	3:55 pm Eastern Time
Webcast:	The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com.

About Immunovant, Inc. 
Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. For additional information on the Company, please visit www.immunovant.com. 

Contact:
Chau Cheng, PhD, MBA
Vice President, Investor Relations
Immunovant, Inc.
info@immunovant.com 

FAQ

When will Pete Salzmann participate in the fireside chat for Immunovant?

Pete Salzmann will participate in the fireside chat on November 14, 2022, at 3:55 pm Eastern Time.

Where can I watch the Immunovant fireside chat webcast?

The webcast can be accessed through the Investor Relations section of Immunovant's website at www.immunovant.com.

What is the purpose of the Guggenheim 4th Annual Immunology and Neurology Day?

The Guggenheim 4th Annual Immunology and Neurology Day focuses on advancements in immunology and neurology, featuring discussions from industry leaders like Immunovant.

What is Immunovant's focus in biopharmaceuticals?

Immunovant is dedicated to developing innovative therapies for autoimmune diseases using FcRn inhibitor technology.